Knowing what's growing: Why ductal and intraductal prostate cancer matter

Mitchell G. Lawrence; Laura H. Porter; David Clouston; Declan G. Murphy; Mark Frydenberg; Renea A. Taylor; Gail P. Risbridger

doi:10.1126/scitranslmed.aaz0152

Knowing what's growing: Why ductal and intraductal prostate cancer matter

Mitchell G. Lawrence, Laura H. Porter, David Clouston, Declan G. Murphy, Mark Frydenberg, Renea A. Taylor, Gail P. Risbridger

Research output: Contribution to journal › Review Article › Research › peer-review

27 Citations (Scopus)

Abstract

Prostate cancer is a common malignancy, but only some tumors are lethal. Accurately identifying these tumors will improve clinical practice and instruct research. Aggressive cancers often have distinctive pathologies, including intraductal carcinoma of the prostate (IDC-P) and ductal adenocarcinoma. Here, we review the importance of these pathologies because they are often overlooked, especially in genomics and preclinical testing. Pathology, genomics, and patient-derived models show that IDC-P and ductal adenocarcinoma accompany multiple markers of poor prognosis. Consequently, "knowing what is growing" will help translate preclinical research to pinpoint and treat high-risk prostate cancer in the clinic.

Original language	English
Article number	aaz0152
Number of pages	15
Journal	Science Translational Medicine
Volume	12
Issue number	533
DOIs	https://doi.org/10.1126/scitranslmed.aaz0152
Publication status	Published - 4 Mar 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1126/scitranslmed.aaz0152

Cite this

@article{b74fda46c6984ea5979514e5a9396e96,

title = "Knowing what's growing: Why ductal and intraductal prostate cancer matter",

abstract = "Prostate cancer is a common malignancy, but only some tumors are lethal. Accurately identifying these tumors will improve clinical practice and instruct research. Aggressive cancers often have distinctive pathologies, including intraductal carcinoma of the prostate (IDC-P) and ductal adenocarcinoma. Here, we review the importance of these pathologies because they are often overlooked, especially in genomics and preclinical testing. Pathology, genomics, and patient-derived models show that IDC-P and ductal adenocarcinoma accompany multiple markers of poor prognosis. Consequently, {"}knowing what is growing{"} will help translate preclinical research to pinpoint and treat high-risk prostate cancer in the clinic.",

author = "Lawrence, {Mitchell G.} and Porter, {Laura H.} and David Clouston and Murphy, {Declan G.} and Mark Frydenberg and Taylor, {Renea A.} and Risbridger, {Gail P.}",

year = "2020",

month = mar,

day = "4",

doi = "10.1126/scitranslmed.aaz0152",

language = "English",

volume = "12",

journal = "Science Translational Medicine",

issn = "1946-6234",

publisher = "American Association for the Advancement of Science (AAAS)",

number = "533",

}

TY - JOUR

T1 - Knowing what's growing

T2 - Why ductal and intraductal prostate cancer matter

AU - Lawrence, Mitchell G.

AU - Porter, Laura H.

AU - Clouston, David

AU - Murphy, Declan G.

AU - Frydenberg, Mark

AU - Taylor, Renea A.

AU - Risbridger, Gail P.

PY - 2020/3/4

Y1 - 2020/3/4

N2 - Prostate cancer is a common malignancy, but only some tumors are lethal. Accurately identifying these tumors will improve clinical practice and instruct research. Aggressive cancers often have distinctive pathologies, including intraductal carcinoma of the prostate (IDC-P) and ductal adenocarcinoma. Here, we review the importance of these pathologies because they are often overlooked, especially in genomics and preclinical testing. Pathology, genomics, and patient-derived models show that IDC-P and ductal adenocarcinoma accompany multiple markers of poor prognosis. Consequently, "knowing what is growing" will help translate preclinical research to pinpoint and treat high-risk prostate cancer in the clinic.

AB - Prostate cancer is a common malignancy, but only some tumors are lethal. Accurately identifying these tumors will improve clinical practice and instruct research. Aggressive cancers often have distinctive pathologies, including intraductal carcinoma of the prostate (IDC-P) and ductal adenocarcinoma. Here, we review the importance of these pathologies because they are often overlooked, especially in genomics and preclinical testing. Pathology, genomics, and patient-derived models show that IDC-P and ductal adenocarcinoma accompany multiple markers of poor prognosis. Consequently, "knowing what is growing" will help translate preclinical research to pinpoint and treat high-risk prostate cancer in the clinic.

UR - http://www.scopus.com/inward/record.url?scp=85081402511&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aaz0152

DO - 10.1126/scitranslmed.aaz0152

M3 - Review Article

C2 - 32132214

SN - 1946-6234

VL - 12

JO - Science Translational Medicine

JF - Science Translational Medicine

IS - 533

M1 - aaz0152

ER -

Knowing what's growing: Why ductal and intraductal prostate cancer matter

Abstract

UN SDGs

Access to Document

Other files and links

Intraductal carcinoma of the prostate: indicator of aggressive disease.

Monash Histology Platform (MHP)

Cite this

Knowing what's growing: Why ductal and intraductal prostate cancer matter

Abstract

UN SDGs

Access to Document

Other files and links

Projects

Intraductal carcinoma of the prostate: indicator of aggressive disease.

Equipment

Monash Histology Platform (MHP)

Cite this